

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	REILLY ET AL.	Examiner:	C. CROWDER
Serial No.:	10/697,995	Group Art Unit:	1644
Filed:	OCTOBER 30, 2003	Docket No.:	11669.195USU1
Confirmation No.:	7395	Customer No.:	23552
Title:	METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION		

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This paper is being submitted in response to the Restriction Requirement mailed March 22, 2006. Without acquiescing to the statements made therein, Applicants hereby elect the claims of Group II (claims 55-101 and 103-114), with traverse, for prosecution in the instant application.

Applicants traverse the restriction with respect to Group III, claims 115 and 117-120, and Group IV, claim 116. Applicants submit that the Examiner has not established that it would be unduly burdensome to search the subject matter of these claims. Applicants submit a search of the subject matter of claims 55-101 and 103-114 is likely to include the subject matter of claims 115, and 117-120. With respect to Group IV, the Examiner indicates the subject matter of claim 116 is found in the same class as that of subject matter of Group II, claims 55-101 and 103-114. Applicants also submit search of the subject matter of claims 55-101 and 103-114 is likely to include the subject matter of claims 116.

The Examiner has also required an election of species. Since Applicants have elected Group II, claims 55-101 and 103-114, Applicants elect the following species: an antibody specific for VEGF; and is an antagonist. Applicants further elect E.Coli host cells, DsbA, and the heavy and light chains are encoded by a single polynucleotide.

Applicants submit claims 55-85, 87-101, and 103-114 are readable on and/or generic to the elected species. Claim 86 includes non-elected species. If a generic claim is found allowable, the Examiner must search the additional species of those claims.

Interview Summary

Applicants thank Examiner Crowder for the interview on April 27, 2006. We discussed the grouping of method claims 66-101 in group II (polynucleotide claims). The Examiner checked with her supervisor and indicated that the grouping was correct. Applicants' representative pointed out linking claims and rejoinder practice.

Examination on the merits is respectfully requested.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: May 5, 2006

Katherine Kowalchyk
Katherine M. Kowalchyk
Reg. No. 36,848

